Dataset from A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/00005134
下载链接
链接失效反馈官方服务：
资源简介：
This is a Phase IIIb multicenter study to evaluate the safety and efficacy of certolizumab pegol (CZP) administered to patients with moderate-to-severe rheumatoid arthritis.
创建时间：
2025-02-22
